Navigation Links
PI-88 Data to be Presented at Key International Conferences

BRISBANE, Australia, March 12, 2007: Progen Industries Limited (ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL). Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007.


In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007.


Dr. Anand Gautam, Progen's VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles, U.S, from April 14-18, 2007.


About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.


Progen's three key areas of focus are:

* Clinical Development - via a focused clinical trial program involving its two compounds PI-88 and PI-166.

* Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes.

* Manufacturing Services - PI-88 manufacturing development and supply for the clinical program and contract manufacturing services.


Keywords - Progen, liver cancer, PI-88.

Web links to selected recent news and other information about
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Data Presented Key International Conferences
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... First Commercial Market to Demonstrate Test,s Potential for ... ... ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced ... The test searches for a unique gene expression signature,identified by DiaGenic using ...
... Drug was Well-Tolerated, Significantly Inhibited ... on Monday, November 10 at 8:30 ... a.m. ET-, ... VIAP ), a biotechnology company focused on,the development of compounds for the treatment ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... potential role of Eph receptor and ephrin ligand family ... other Eph receptors, EphA4 is distinguished by its ability ... type B ephrins. EphA4 reportedly forms a hetero receptor ... downstream signal transduction. However, alterations of EphA4 are not ...
... association of DM2 with solid tumors, and particularly with ... reported increased mortality rates for neoplastic diseases in patients ... diabetes and development of HCC, and the clinical and ... not been well examined. , A research article to ...
... 29 Abbott (NYSE: ABT ),will present at ... Nov. 12. Thomas C. Freyman, executive vice president, finance,and ... company at 5,p.m. CST., A live audio webcast ... Web site at http://www.abbottinvestor.com . An,archived edition of ...
... PRUSSIA, Pa., Oct. 29 HighPoint,Solutions LLC, a premier ... of its growth strategy, it has expanded its,presence in ... new location will,be at 8750 W. Bryn Mawr, Suite ... located near O,Hare International,Airport., Glenn Becker, HighPoint Solutions, ...
... N.J., Oct. 29 Derma Sciences, Inc.,(OTC Bulletin Board: ... it will present at the upcoming Rodman & Renshaw ... Palace Hotel in,New York City. The Company is scheduled ... Adams room located on the 4th floor., Management ...
... Drive Company,s Latest Learning Technology, ORLANDO, Fla., ... a leading provider of educational enterprise technology,announced today ... Release 9.0,featuring nearly 50 institutions that are now ... of the Beta program are evaluating and providing ...
Cached Medicine News:Health News:If the diabetes has a direct carcinogenetic effect? 2Health News:HighPoint Solutions Expands with New Chicago Office 2Health News:Derma Sciences to Present at The Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Blackboard Announces Launch of Beta Program 2Health News:Blackboard Announces Launch of Beta Program 3Health News:Blackboard Announces Launch of Beta Program 4
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed....
... Standard/Conventional. Stainless steel. Lamp supplied with ... high quality standard incandescent laryngoscope blades. The ... refined through many years of use the ... are manufactured to exacting specifications from the ...
... Blade. Stainless Steel. Lamp supplied with ... of high quality standard incandescent laryngoscope ... have been continually refined through many ... to minimize maintenance requirements. They are ...
Medicine Products: